GSK plc (NYSE:GSK) Shares Sold by Financial Counselors Inc.

Financial Counselors Inc. trimmed its holdings in shares of GSK plc (NYSE:GSK) by 2.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 148,230 shares of the pharmaceutical company’s stock after selling 3,991 shares during the period. Financial Counselors Inc.’s holdings in GSK were worth $5,707,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Natixis Advisors LLC lifted its position in GSK by 10.4% during the second quarter. Natixis Advisors LLC now owns 417,062 shares of the pharmaceutical company’s stock valued at $16,057,000 after buying an additional 39,346 shares in the last quarter. Essex Financial Services Inc. raised its stake in shares of GSK by 41.3% during the second quarter. Essex Financial Services Inc. now owns 7,234 shares of the pharmaceutical company’s stock valued at $281,000 after purchasing an additional 2,116 shares during the period. Aptus Capital Advisors LLC raised its stake in shares of GSK by 13.3% during the second quarter. Aptus Capital Advisors LLC now owns 5,521 shares of the pharmaceutical company’s stock valued at $213,000 after purchasing an additional 646 shares during the period. Farther Finance Advisors LLC raised its stake in shares of GSK by 52.3% during the second quarter. Farther Finance Advisors LLC now owns 6,057 shares of the pharmaceutical company’s stock valued at $232,000 after purchasing an additional 2,081 shares during the period. Finally, Advisors Management Group Inc. ADV raised its stake in shares of GSK by 1.2% during the second quarter. Advisors Management Group Inc. ADV now owns 82,447 shares of the pharmaceutical company’s stock valued at $3,174,000 after purchasing an additional 991 shares during the period. 15.74% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GSK has been the topic of a number of analyst reports. Berenberg Bank upgraded shares of GSK to a “strong-buy” rating in a research note on Thursday, June 20th. UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Barclays upgraded shares of GSK to a “hold” rating in a research note on Tuesday, August 27th. Jefferies Financial Group lifted their price objective on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. Finally, The Goldman Sachs Group began coverage on shares of GSK in a research note on Thursday, May 30th. They issued a “neutral” rating and a $47.00 price target for the company. Four equities research analysts have rated the stock with a hold rating, two have given a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat, GSK has a consensus rating of “Buy” and a consensus price target of $50.00.

GSK Stock Performance

GSK stock opened at $43.91 on Tuesday. The company has a market cap of $91.00 billion, a PE ratio of 15.91, a P/E/G ratio of 1.42 and a beta of 0.64. The company has a fifty day moving average price of $40.17 and a two-hundred day moving average price of $41.60. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54. GSK plc has a 12 month low of $33.67 and a 12 month high of $45.92.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 10th. Shareholders of record on Friday, August 16th will be issued a $0.3843 dividend. This represents a $1.54 dividend on an annualized basis and a yield of 3.50%. The ex-dividend date is Friday, August 16th. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s payout ratio is currently 54.71%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.